Showing 1 - 10 of 95
used in chemistry, pharmacokinetics or microbiology. We propose a maximin approach, which determines the optimal design …
Persistent link: https://www.econbiz.de/10010306252
used in chemistry, pharmacokinetics or microbiology. We propose a maximin approach, which determines the optimal design …
Persistent link: https://www.econbiz.de/10010514263
In this paper, we describe an adjusted method to facilitate a non-inferiority trial by a three-arm robust design. Because local optimal designs derived in Hasler et al. [2007] require knowledge about the ratios of the population variances and are not necessarily robust with respect to possible...
Persistent link: https://www.econbiz.de/10010298205
In this paper, we describe an adjusted method to facilitate a non-inferiority trial by a three-arm robust design. Because local optimal designs derived in Hasler et al. [2007] require knowledge about the ratios of the population variances and are not necessarily robust with respect to possible...
Persistent link: https://www.econbiz.de/10009219855
Persistent link: https://www.econbiz.de/10008776717
For the Weibull- and Richards-regression model robust designs are determined by maximizing a minimum of D- or D1-efficiencies, taken over a certain range of the non-linear parameters. It is demonstrated that the derived designs yield a satisfactory solution of the optimal design problem for this...
Persistent link: https://www.econbiz.de/10010296675
For the Weibull- and Richards-regression model robust designs are determined by maximizing a minimum of D- or D1-efficiencies, taken over a certain range of the non-linear parameters. It is demonstrated that the derived designs yield a satisfactory solution of the optimal design problem for this...
Persistent link: https://www.econbiz.de/10009219810
The pharmacokinetic (PK) analysis of breast MRI data using prior methods like the Tofts model-based approaches involved the estimation of the amount of contrast agent (CA) fed to the tissue, called the Arterial Input Function (AIF). The Mohan-Shinagawa model (hence-forth referred to as the M-S...
Persistent link: https://www.econbiz.de/10009475808
Background and Objectives:Background and Objectives: Economic value is an important consideration during all phases of the drug development process. We previously published an article in PharmacoEconomics in which we described a mechanism-based economic modelling approach that incorporates data...
Persistent link: https://www.econbiz.de/10010541098
Simulation is widely used to investigate real-world systems in a large number of fields, including clinical trials for drug development, since real trials are costly, frequently fail and may lead to serious side effects. This paper is a survey of the statistical issues arising in these simulated...
Persistent link: https://www.econbiz.de/10011228116